OTTAWA, April 25 /CNW Telbec/ - The Canadian Agency for Drugs and
Technologies in Health (CADTH) today announced the release of Optimal Therapy
Reports and Intervention Tools for the prescribing and use of proton pump
inhibitors (PPIs) through its Canadian Optimal Medication Prescribing and
Utilization Service (COMPUS).
Barb Shea, Vice-President of CADTH's COMPUS program, noted the
significance of this achievement.
"COMPUS Optimal Therapy Reports and Tools support health care providers,
decision makers and consumers in making decisions on drug therapy. We are
confident that through the uptake and adoption of reliable information on drug
prescribing and use, health outcomes in Canada can be improved, and health
care resources targeted more effectively."
The Optimal Therapy Reports on PPIs include a scientific report
containing evidence-based statements for PPI use in gastroesophageal reflux
disease (GERD), dyspepsia and peptic ulcer disease, as agreed upon by the
COMPUS Expert Review Panel on PPIs; economic models and conclusions for the
treatment of dyspepsia, heartburn associated with GERD, and the prevention of
non-steroidal anti-inflammatory drug (NSAID)-induced gastrointestinal
complications; a literature review of interventions for the appropriate
prescribing of PPIs; a current-practice analysis of the prescribing and use of
PPIs in Canada; a gap analysis comparing current practice with the evidence;
and a report on the COMPUS selection of interventions for the PPI project.
Intervention tools - designed to influence behaviour change - have also
been released to assist jurisdictions in implementing COMPUS information. The
first of these tools comprise components of an academic detailing program that
can be used by health care providers and consumers. Other intervention tools
will be released in May and June of this year. All COMPUS reports and tools
can be found on the CADTH web site at www.cadth.ca.
The Canadian Agency for Drugs and Technologies in Health (CADTH) is a
national body that provides Canada's federal, provincial, and territorial
health care decision makers with credible, impartial advice and evidence-based
information about the effectiveness and efficiency of drugs and other health
For further information:
For further information: visit www.cadth.ca or contact: Janet Crain,
Senior Communications Advisor, Canadian Agency for Drugs and Technologies in
Health, (613) 226-2553, email@example.com